CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

August 30th, 2010

Study Finds African-Americans at Increased Risk for Stent Thrombosis

African-Americans are nearly three times more likely than other races to develop stent thrombosis after receiving a drug-eluting stent, according to a new study appearing in Circulation. Ron Waksman and colleagues analyzed data from a large, single-center registry of 7,236 patients who received a DES and found that African-American race was the single strongest predictor of late stent thrombosis — even after accounting for other known risk factors, and even though African-Americans were more likely to comply with their prescriptions for antiplatelet therapy. The rates of stent thrombosis for African-Americans, compared with non-African-Americans, were:

  • 1.71% vs. 0.59% at 30 days;
  • 2.25% vs. 0.79% at 1 year;
  • 2.78% vs. 1.09% at 2 years;
  • 3.67% vs. 1.25% at 3 years.

Overall mortality at 3 years was also higher among African-Americans: 24.9% versus 13.1% for other races.

In the discussion section, the authors write: “Because the traditional socioeconomic factors that plague racial disparities in health care have been accounted for in our study, further mechanisms such as genetic differences by which black race predicts ST [stent thrombosis] must be pursued.”

Categories: Uncategorized
Tags: , , ,


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

One Response to “Study Finds African-Americans at Increased Risk for Stent Thrombosis”

  1. ABOUBAKER EL-AGNAF, MD, MRCP,FRCP,DIM,FSCIA,MCS says:
    September 19, 2010 at 2:16 am

    this will be a warning to all african cardiologists when they try to insert DES to an african patinets living in africa.
    infact this highlite the urgency and needs to conduct our own trials and derive our own data in africa and not to depend to import international data and and try to apply it on our patients in africa.
    and this clearly highlite the importance of differences of genotype in response to treatment which include DES.